Mesoblast Ltd has released a press release.
COVID ARDS Trial Topline 60-Day Results
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Earlier from Mesoblast
- Mesoblast Raises US$110M Led By US Strategic Investor Group
- Mesoblast Phase 3 Chronic Low Back Pain Results
- Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
- Mesoblast Update on COVID-19 ARDS Trial
- Trading halt
Later from Mesoblast
- MSB Reports Q3 Financial Results and Operational Highlight
- Mesoblast Update on Chronic Low Back Pain Program
- MSB Annual Financial Results and Operational Progress
- AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
- MSB and Oaktree Conclude Refinancing of Senior Debt Facility
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast